Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial.
暂无分享，去创建一个
J. Blanco | B. Trinité | L. Leal | A. Prenafeta | J. Pich | N. Izquierdo-Useros | C. Pastor | I. Esteban | R. Martí-Lluch | J. Arnaiz | M. Nadal | M. Plana | E. Pradenas | T. Prát | R. Ramos | L. Ferrer | J. Nava | D. Raich-Regue | K. Escobar | M. Ribas-Aulinas | J. Muñoz-Basagoiti | G. Domenech | B. Clotet | J. Corominas | A. Corpes-Comes | C. Garriga | A. Barreiro | A. Soriano | J. Rios | E. Torroella | J. Muñoz‐Basagoiti